Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Heart Repolarization
Interventions: Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Smoking
Interventions: cognitive behavior therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Nicotine Dependence, Tobacco Use
Interventions: Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain; Drug · Behavioral
Lead sponsor: Mark Vander Weg; Other
Eligibility: 18 Years to 99 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pregnancy Related, Tobacco Use Disorder
Interventions: Bupropion SR, Smoking Cessation Counseling, Placebo; Drug · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Depression
Interventions: Escitalopram, Bupropion XL; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Treatment Resistant Depression, Major Depressive Disorder
Interventions: AXS-05 (dextromethorphan-bupropion); Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more

Conditions: Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions: Aromatase Inhibitors, Bupropion, GnRH agonist; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease
Interventions: Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Overweight
Interventions: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more

Conditions: Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Bupropion 150 mg XL, Placebo; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 362
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 262 more

Conditions: Dysthymic Disorder
Interventions: bupropion XL, Placebo; Drug · Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use Disorder/Cigarette Smoking, HIV
Interventions: nicotine patch, nicotine gum, nicotine lozenge, varenicline, bupropion, Multi-target Contingency Management, Teamlet booster; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 5
States / cities: Bridgeport, Connecticut • New Haven, Connecticut • Jersey City, New Jersey + 2 more

Conditions: Nicotine Dependence, Schizophrenia
Interventions: NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone Hydrochloride, Bupropion HCl Extended Release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Loss-of-Control Eating, Obesity/Overweight
Interventions: Naltrexone and Bupropion (NB) medication, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking Cessation
Interventions: Intervention Arm; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Substance Abuse, HIV Infections
Interventions: Bupropion, Placebo; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Smoking
Interventions: Varenicline, placebo, bupropion SR; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Rochester, Minnesota • La Crosse, Wisconsin

Conditions: Depression, Bipolar Disorder
Interventions: bupropion SR; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Weight Regain Post Bariatric Surgery
Interventions: Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Bupropion SR, placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Behavioral Maintenance Treatment for Smoking Cessation

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

Bupropion for Smoking Cessation During Pregnancy

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Voxelotor CYP and Transporter Cocktail Interaction Study

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Wellbutrin XL for Dysthymic Disorder

Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Embedding Comprehensive Smoking Cessation Programs Into Community Clinics

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Varenicline and Bupropion for Smoking Cessation

Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women